February 16, 2016 Synthetic Biologics to Participate in Fireside Chat at RBC Capital Markets' Global Healthcare Conference
February 2, 2016 Synthetic Biologics Reports Results of Independent Third Party Evaluations of Trimesta™ Data from Investigator-Sponsored Phase 2 Clinical Trial for Relapsing-Remitting Multiple Sclerosis
January 19, 2016 Synthetic Biologics Reports Positive Topline Data from Second Phase 2 Clinical Trial of SYN-010 in Patients with Irritable Bowel Syndrome with Constipation (IBS-C)
December 8, 2015 Synthetic Biologics' SYN-010 Lowered Breath Methane and Improved Stool Frequency in a Phase 2 Four Week Study in Patients with Irritable Bowel Syndrome with Constipation (IBS-C)
December 1, 2015 Synthetic Biologics Announces Positive Topline Results from First Phase 2a Clinical Trial of SYN-004, the Company's Candidate for the Prevention of C. difficile Infection
November 25, 2015 Synthetic Biologics Reports that Data from the Phase 2 Trimesta™ Clinical Trial for Relapsing-Remitting Multiple Sclerosis were Published by Lead Principal Investigator
November 24, 2015 Synthetic Biologics Announces Issuance of First Key U.S. Patent Directly Covering SYN-010, the Company's Novel Candidate for Irritable Bowel Syndrome with Constipation (IBS-C)
